Abstract: The invention provides methods for analyzing and predicting the in vivo respiratory toxicity of a compound (e.g., pharmaceutical, biological, cosmetic, or chemical compounds) or composition comprising a combination of an in vitro mammalian cell model with multiple endpoint analysis, and time and concentration response curves. The methods allow the determination of a predicted in vivo respiratory toxicity value of a compound without the use of animals, with a high degree of accuracy. The methods comprise detecting any combination of cell viability markers and expression levels of genes implicated in respiratory toxicity and/or sensitization, such as pro-inflammatory response genes, combining the viability and gene expression level data with concentration response and time response data, conducting a computational analysis, and comparing test compound data to a database of known respiratory toxicants/sensitizers to predict and/or analyze the respiratory toxicity.

Abstract: Methods of evaluating an anti-tumor compound based on in vitro assays are disclosed. The methods may determine a potency/efficacy of the anti-tumor compound as well as a toxicity of the anti-tumor compound to non-cancerous cells.

Abstract: In vitro methods for predicting in vivo toxicity of chemical compounds, including organ-specific and multiple organ toxicity of such chemical compounds and drug-drug interactions, understanding the relative toxicity of drug candidates and identifying mechanisms of toxicity, are disclosed.

Abstract: The present invention provides methods of determining a level of toxicity of a given compound based on in vitro assays. The present invention provides particular methods of determining organ-specific toxicity and species-specific toxicity of a given compound based on in vitro assays. In addition, the present invention provides methods of determining a level of toxicity in normal tissue for an anti-tumor compound. The methods include providing at least one cell type and culturing the cell type in the presence of at least one concentration of the chemical compound, measuring at least one indicator of cell health at the at least one concentration of compound for the at least one cell type, and performing a concentration response analysis, from which a toxic concentration can be determined.

Abstract: The invention provides methods for analyzing and predicting the in vivo respiratory toxicity of a compound (e.g., pharmaceutical, biological, cosmetic, or chemical compounds) or composition comprising a combination of an in vitro mammalian cell model with multiple endpoint analysis, and time and concentration response curves. The methods allow the determination of a predicted in vivo respiratory toxicity value of a compound without the use of animals, with a high degree of accuracy. The methods comprise detecting any combination of cell viability markers and expression levels of genes implicated in respiratory toxicity and/or sensitization, such as pro-inflammatory response genes, combining the viability and gene expression level data with concentration response and time response data, conducting a computational analysis, and comparing test compound data to a database of known respiratory toxicants/sensitizers to predict and/or analyze the respiratory toxicity.

Abstract: The present invention provides methods for predicting the in vivo skin sensitizing activity of chemical compounds using a combination of mammalian cell models with multiple endpoint analysis, time and concentration response curves. The methods allow the determination of a predicted in vivo sensitization value of a compound—for example, a EC3 LLNA value, a GPMT value or a IVTI value—without the use of animals, with a high degree of accuracy. The methods involve detecting expression levels of genes implicated in skin sensitization, combining expression level data with concentration response data, conducting a computational analysis, and comparing test compound data to a database of known skin sensitizers.

Abstract: The present invention provides methods of determining a level of toxicity of a given compound based on in vitro assays. The present invention provides particular methods of determining organ-specific toxicity and species-specific toxicity of a given compound based on in vitro assays. In addition, the present invention provides methods of determining a level of toxicity in normal tissue for an anti-tumor compound. The methods include providing at least one cell type and culturing the cell type in the presence of at least one concentration of the chemical compound, measuring at least one indicator of cell health at the at least one concentration of compound for the at least one cell type, and performing a concentration response analysis, from which a toxic concentration can be determined.

Abstract: The present invention provides materials and methods for predicting the in vivo toxicity of a given compound. For example, the invention comprises conducting at least three distinct assays in parallel to provide information about three distinct parameters of cytotoxicity of a chemical in a given target cell, which information is useful for predicting in vivo cytotoxicity.